^
    3d
    Entrectinib attenuates LPS-induced neuroinflammation by inhibiting JNK, p38, and AKT pathways and ameliorates cognitive impairment. (PubMed, Arch Pharm Res)
    Notably, Entrectinib ameliorated LPS-induced memory impairments in vivo. Collectively, these findings indicate that Entrectinib attenuates neuroinflammation and improves memory performance, supporting its potential therapeutic relevance for neuroinflammation-associated cognitive disorders.
    Journal
    |
    MRC1 (Mannose Receptor C-Type 1)
    |
    Rozlytrek (entrectinib)
    5d
    Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Novartis Pharmaceuticals | Trial primary completion date: Nov 2027 --> Nov 2026
    Trial primary completion date
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    6d
    IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy. (PubMed, Front Immunol)
    This mechanism of antigen loss can be rescued with anti-IFNγ neutralizing antibody, the JAK inhibitor ruxolitinib, or 4-phenylbutyrate (an ER stress reliever). We revealed a negative effect of IFNγ that uniquely interferes with immunotherapies targeting native surface antigens, such as CART and BiTE therapies, which may be reversed by disrupting stress signaling pathways to enhance solid tumor CART and BiTE immunotherapies.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • GUCY2C (Guanylate Cyclase 2C)
    |
    Jakafi (ruxolitinib)
    6d
    Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently. (PubMed, NPJ Precis Oncol)
    In contrast, other JAK-STAT3 inhibitors such as ruxolitinib and knockdown of STAT3 does not replicate this effect, indicating that the anti-tumor effect of filgotinib is independent of JAK-STAT3 signaling. This study offers innovative insights and potential therapeutic strategies for the treatment of PDAC through EIF3A m6A.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • EIF6 (Eukaryotic Translation Initiation Factor 6) • METTL3 (Methyltransferase Like 3)
    |
    Jakafi (ruxolitinib)
    6d
    cHL-PG01: A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL) (2024-520123-83-01)
    P1/2, N=48, Active, not recruiting, Universita' Degli Studi Di Perugia | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Keytruda (pembrolizumab) • Jakafi (ruxolitinib) • Adcetris (brentuximab vedotin)
    7d
    The Evaluation of Neurotrophic Receptor Tyrosine Kinase (NTRK) Alterations in Neuroblastomas. (PubMed, Front Biosci (Schol Ed))
    Owing to the presence of neural tissue, NTRKs are highly positive in IHC, making these genes unsuitable as biomarkers for assessing NTRK inhibitor sensitivity and resistance, which are tissue-agnostic drugs. The observed low fusion rate is consistent with the literature, and the significance of the numerous point mutations identified as agnostic markers warrants further investigation. NTRK expression, fusion, and point mutations were not associated with clinical parameters or survival.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Chr del(11q) • MYCN amplification • NTRK positive • NTRK fusion
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
    7d
    Ruxolitinib reverses systemic vasculitis driven by JAK2 V617F-mutated essential thrombocythemia: a case report. (PubMed, Front Immunol)
    Treatment with hydroxycarbamide and ruxolitinib resulted in decreased platelet counts and improved vasculitis, with no subsequent recurrence of cardiovascular events. This rare case shows that ruxolitinib can be effective in treating vasculitis complications in patients with JAK2 mutation-positive ET.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib) • hydroxyurea
    7d
    NCI-2013-00704: Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (clinicaltrials.gov)
    P2, N=121, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> Jan 2026 | Trial primary completion date: Apr 2027 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    azacitidine • Jakafi (ruxolitinib)
    8d
    P30CA015704: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=61, Completed, Fred Hutchinson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    11d
    Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts (clinicaltrials.gov)
    P4, N=268, Not yet recruiting, SWOG Cancer Research Network
    New P4 trial
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    11d
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Ojjaara (momelotinib)